



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

Mr. Robert Hill
Regulatory Manager
Terang Nusa Sdn Bhd
1, Jalan 8, Pengkalan Chepa 2 Ind. Zone
Kota Bharu Kelantan
MALAYSIA 16100

DEC - 7 2011

Re: K110698
Trade/Device Name: Nuzone X2T
Regulation Number: 21 CFR 878.4460
Regulation Name: Surgeon's Glove
Regulatory Class: I
Product Code: KGO
Dated: December 5, 2011
Received: December 5, 2011

Dear Mr. Hill:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Mr. Hill

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number: K110698

Device Name: Nuzone X2T

Description: Polychloroprene Synthetic Tan Surgical gloves Powder Free

Indications for Use: This Surgeons Glove is a device made of synthetic rubber intended to be worn by operating room personnel to protect a surgical wound from contamination. The lubricating or dusting powder used in the glove is excluded.

Prescription Use _____
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use X
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) _____


(Division Sign-Off)

Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K 110698

510(k) Number: K110698

Device Name: Nuzone X2T

Continued:

These gloves are tested for use with Chemotherapy Drugs.

Testing based on ASTM D6978-05

DRUG	Breakthrough Detection Time
Carmustine (BCNU) 3.3 mg/ml (3,300 ppm)	Avg. 5.18 (6.55, 5.95, 3.04) Minutes
Cisplatin 1.0 mg/ml (1,000 ppm)	Up to 240 Minutes
Cyclophosphamide (Cytoxan) 20.0 mg/ml (20,000 ppm)	Up to 240 Minutes
Dacarbazine (DTIC) 10.0 mg/ml (10,000 ppm)	Up to 240 Minutes
Doxorubicin Hydrochloride 2.0 mg/ml (2,000 ppm)	Up to 240 Minutes
Etoposide (Toposar) 20.0 mg/ml (20,000 ppm)	Up to 240 Minutes
Paclitaxel (Taxol) 6.0 mg/ml (6,000 ppm)	Up to 240 Minutes
Fluorouracil 50.0 mg/ml (50,000 ppm)	Up to 240 Minutes
Thiotepa 10.0 mg/ml (10,000 ppm)	Avg. 3.03 (6.41, 1.63, 1.06) Minutes
Vincristine Sulfate 50.0 mg/ml (50,000 ppm)	Up to 240 Minutes

Please note that the following drugs have extremely low permeation times Carmustine (BCNU) of 5.18 and Thiotepa of 3.03 minutes.